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Soyand BreastCancer
Protection MayVaryby Doseand Age
Soyfoods, rich in plantestrogens, have beenembraced
by American women seeking relief from menopause
without thebreastcancerriskassociatedwithsynthetic
hormones. Because Asian women consume soy-based
diets but have a low incidence ofbreast cancer, it has
been suggested that soy prevents cancer, perhaps by
reducing estrogen levels. Asian women living in Asia
have serum estrogen levels as much as 40% lower than
U.S. women and demonstrate a fivefold lower risk of
developing breast cancer.
The link between soy and cancer prevention is far
from conclusive, though, as Kerrie B. Bouker and
Leena Hilakivi-Clarke of Georgetown University's
Lombardi Cancer Center inWashington, DC, demon-
stratewith theirsummaryofresearch on soy's effects on
the breast [EHP 108:701-708]. The researchers sug-
gest that for postrmenopausal women in the United States, soy may
actuallyhave estrogeniceffects.
- ~~~~~~~~~~~~~~~~~~~1
Soy potential uncertain.
Several factors may influence
whether plant estrogens such
as those found in soy have
estrogenic or antiestrogenic
effects.
Soy's assumed anticancerpotential is associated with its rich supply
ofphytoestrogens, particularly genistein. A number of in vitro studies
have shown genistein to suppress estrogenic activity, possibly by
inhibiting estrogen-metabolizing enzymes. Animal experiments and
studies with human breast cancer cells have demonstrated genistein's
capacity to repress cell growth. Yet in vivo and in vitro models have
also shown genistein to be estrogenic. Genistein is structurally similar
to steroidal estrogens and binds to estrogen receptors. Like estrogen, it
also helps build bone density, improves lipid profiles, and may reduce
the riskofheartdisease.
The paradox ofgenistein's estrogenic and antiestrogenic properties
may be related to dose. Studies show that doses higher than can be
achieved only by consuming soy-based foods provide protection
against breastcancersimilar to thedrug tamoxifen. At doses achievable
by consuming foods high in soy, genistein stimulates
the growth of human breast cancer cells. However, a
study of postmenopausal American women given 38
grams of soy protein isolate daily for 5 months (the
amount they would get in a high-soy diet) showed no
changes.
Genistein's effect also may depend on a woman's
age during exposure. Rat studies show that in utero
exposure to genistein but not to soyincreases the risk of
breast cancer. Another vulnerable stage for genistein
exposure appears to be the years following menopause;
animal studies with ovariectomized mice (a model of
postmenopause) suggest that genistein increases breast
cancer risk. However, no increase in risk is seen in ani-
mals exposed during their reproductive stage, and rats
exposed to genistein before puberty show low breast
cancerrisk.
Asian women, however, eat a soy-based diet
throughout pregnancy without raising their daughters'
risk. Bouker and Hilakivi-Clarke speculate thatAsian women's protec-
tion stems from their lifelong exposure. They also suggest that other
components of soy such as saponins and phytic acids may temper
genistein's estrogenic effects inhumans.
The researchers theorize that genistein's varying effects may be a
function ofwomen's estrogen levels. When levels are low, as before
puberty, genistein may act as an estrogen. Animal and human studies
suggest that estrogen exposure before puberty paradoxically reduces
breast cancer risk. The researchers also suggest that the phytoestrogen
promotes the proliferation ofmammarycells inwomen ofall ages, but
that because older women may already have malignant cells in their
breasts, they're morelikely todevelop cancer.
In light ofevidence suggesting that genistein may promote cancer,
Bouker and Hilakivi-Clarke call for more studies ofits effects. They
believe explanations for the phytoestrogen's dual nature are close at
hand. -Cynthia Washam
Inhalation of Radiation
Low DosesYield High Risks
Through studies oflarge groups exposed to radiation, epidemiolo-
gists try to quantify the relationship between doses received and
resulting carcinogenic effects. Such information is used in the
establishment of radiation protection standards. Many radiation
exposures today, particularly those of workers in certain types of
nuclear facilities, occur when radioactive materials are taken inside
the body. But except for a few cases, few human epidemiological
studies of the health effects of internal exposures have been con-
ducted. So a team ofinvestigators led by epidemiologist Beate Ritz
ofthe University ofCalifornia at LosAngeles launched a retrospec-
tive study of former nuclear employees to assess the long-term
health effects ofradiation exposures primarily due to the inhalation
ofairborne radioactive materials [EHP 108:743-751]. They found
that low internal radiation doses may increase the risk of certain
cancers.
The researchers quantified the doses to nearly 2,300 workers
who had worked at various times between 1950 and 1994 at
Rocketdyne/Atomics International, a nuclear research and develop-
ment facility in Simi Valley, California. The investigators relied pri-
marily on data derived from analysis of specific radionuclides in
worker urine and feces samples. They also perfomed external mea-
surements of the radiation emitted by the radioactive materials in
the subjects' bodies.
In conducting their analyses, Ritz and colleagues separated the
workers into four groups, depending on the dose they were estimat-
ed to have received. The four groups ranged from those who were
not exposed at all to those receiving a maximum dose of 30 milli-
sieverts or more. Acomparison ofthe adjusted rate-ratios for cancers
among these groups showed that the workers who received the high-
est doses died at a substantially higher rate from leukemias and lym-
phomas than did those who were not exposed. The same relation-
ship was true for workers who died from cancers of the mouth,
throat, esophagus, and stomach. Substantiating these observations
was the fact that workers in the zero-dose range had the lowest rates
ofdeath and those within the two intermediate dose ranges had pro-
gressively higher rates ofdeath with increasing dose. Again, this was
true both for leukemias and lymphomas and for cancers of the
mouth, throat, esophagus, and stomach. The researchers also exam-
ined lung, bladder, kidney, and prostate cancer incidence, but found
no elevations in mortality rates. Although the link to increased
leukemias and lymphomas had been reported in two earlier studies,
the relationship to mouth, throat, and esophagus cancers had not
previously been reported forworkers exposed to internally deposited
radionuclides in this low-dose range.
Still, due to the small number ofcases in each cancer group, the
authors are careful to acknowledge that their estimates are imprecise.
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